SPL currently has a market capitalisation of ~$380m
Payments for AZD0466 could be “up to $2.5b” according to JF
Can anyone see where AZ could save about $2b in development costs? Anyone?
One thing JF stated (and I would need to check the presentation again to be sure) was that future drugs to be DEP'd may not even require phase 2 trials. If this is anything more than wishful thinking on JF's part then it would open the floodgates to future revenue streams.
Webinar this Friday 8th April with Jackie Fairley, page-50
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $47.38M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $43.20K | 391.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20946 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 104392 | 6 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
11.3¢ |
Change
0.000 ( 2.17 %) |
||||
| Open | High | Low | Volume | ||
| 11.3¢ | 11.3¢ | 11.0¢ | 82292 | ||
| Last updated 15.58pm 31/05/2024 ? | |||||
| SPL (ASX) Chart |